Oncogene Proteins, Fusion

• 

  Subject Areas on Research

  • "Hairy" cells in acute promyelocytic leukemia: Excess myeloperoxidase with formation of needle-shaped crystalline projections on the cytochemical stain in a case with variant morphology. 
  • A Nanopore Sequencing-Based Assay for Rapid Detection of Gene Fusions. 
  • A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia. 
  • A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. 
  • Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. 
  • Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. 
  • Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. 
  • Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. 
  • Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. 
  • Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. 
  • Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. 
  • Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. 
  • Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. 
  • Dysregulation of hedgehog signalling predisposes to synovial chondromatosis. 
  • Erythrophagocytosis in a cyclin D1 positive plasma cell myeloma with near-tetraploid karyotypic abnormalities and cryptic MYC/IGH fusion. 
  • Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia. 
  • FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. 
  • Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. 
  • Intraventricular Pilocytic Astrocytoma With KIAA1549/BRAF Fusion Arising in a 44-Year Old. 
  • Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis. 
  • Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. 
  • Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. 
  • Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. 
  • Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. 
  • Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. 
  • PAX3-FOXO1 fusion gene in rhabdomyosarcoma. 
  • PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. 
  • Personalized treatment of lung cancer. 
  • Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. 
  • ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer. 
  • Regulation of myeloid leukaemia by the cell-fate determinant Musashi. 
  • Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma. 
  • Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. 
  • Subgroup-specific structural variation across 1,000 medulloblastoma genomes. 
  • Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. 
  • The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas. 
  • The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. 
  • Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide. 
  • t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? 
• 

  Keywords of People

  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Pharmacology & Cancer Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology